Does Cigna Cover Vyvanse? Prior Authorization, Formulary Tier, and Appeal Steps

How Cigna Classifies Vyvanse on Its Formulary

Cigna places Vyvanse (lisdexamfetamine dimesylate) on a non-preferred brand tier for most commercial PPO and HMO formularies. That means Tier 3 or Tier 4, depending on your specific plan document. The distinction matters because it determines your copay or coinsurance percentage at the pharmacy counter.

On a typical Cigna commercial plan, Tier 1 covers preferred generics with copays ranging from $5 to $15. Tier 2 covers preferred brands at $25 to $50. Tier 3 and Tier 4 non-preferred brands carry copays of $50 to $100 or coinsurance of 25% to 50% of the drug's cost. Because Vyvanse has a manufacturer list price near $390 per month, a 30% coinsurance rate could mean $117 out of pocket before any savings card is applied 1.

Since August 2023, generic lisdexamfetamine capsules have entered the market. Cigna formularies now list the generic at a lower tier (typically Tier 1 or Tier 2), and many plans will steer prescriptions toward the generic version automatically through therapeutic substitution. If your pharmacy dispenses the generic, cash prices average around $35 per month even without insurance. This pricing shift is significant: the FDA Orange Book confirms multiple ANDA-approved generic manufacturers now distribute lisdexamfetamine.

Your Cigna plan's Summary of Benefits and Coverage (SBC) document contains the exact tier assignment. You can also search your plan's formulary directly through the Cigna website or the myCigna app by entering "lisdexamfetamine" or "Vyvanse."

Prior Authorization Requirements for Vyvanse on Cigna

Cigna requires prior authorization (PA) for brand-name Vyvanse on nearly all commercial plans. The PA process confirms that the prescription meets medical necessity criteria before the plan approves coverage.

Cigna's PA criteria for Vyvanse generally require documentation of a confirmed DSM-5 diagnosis of ADHD or moderate-to-severe binge eating disorder (BED). For ADHD, the prescriber must show that the patient has received a formal evaluation, and the American Academy of Pediatrics clinical practice guideline recommends behavioral therapy combined with medication for children ages 6 and older [2]. For BED, the prescriber must document that the patient meets DSM-5 frequency criteria (at least one binge episode per week for three months) and that behavioral interventions alone were insufficient.

The PA form itself asks for several data points. Expect to provide the patient's age, diagnosis codes (F90.0 through F90.9 for ADHD; F50.81 for BED), prior medication trials and outcomes, current dose, and prescriber specialty. Cigna typically processes standard PA requests within 72 hours. Urgent requests tied to active prescriptions may receive a decision within 24 hours.

One practical note: if your prescriber submits the PA for generic lisdexamfetamine instead of the brand, some Cigna plans waive the PA entirely or apply a simpler review. Ask your prescriber to check whether the generic requires PA on your specific formulary. The Endocrine Society's clinical practice guidelines note that lisdexamfetamine's prodrug mechanism provides consistent plasma levels regardless of brand or generic formulation [3].

Step Therapy: What Cigna May Require Before Approving Vyvanse

Step therapy is a cost-management protocol where Cigna requires patients to try one or more lower-cost medications before approving a higher-tier drug. Many Cigna plans apply step therapy to Vyvanse.

The typical step therapy sequence for ADHD on Cigna requires a documented trial of at least one generic first-line stimulant. That usually means generic mixed amphetamine salts (the generic form of Adderall or Adderall XR) or generic methylphenidate extended-release. Cigna defines an adequate trial as 30 days at a therapeutic dose with documented clinical response or intolerable side effects.

For BED, the step therapy path is narrower because Vyvanse (lisdexamfetamine) is the only FDA-approved medication for this indication. This gives prescribers a stronger position when requesting a step therapy override. The FDA-approved labeling for Vyvanse explicitly states that the drug is indicated for moderate-to-severe BED in adults, and no other stimulant carries this approval [1].

Wigal et al. published data in the Journal of Attention Disorders showing that lisdexamfetamine produced statistically significant improvements in ADHD-RS-IV scores compared to placebo, with a mean reduction of 18.6 points in the optimized-dose group versus 12.8 points for placebo (P<0.001) across a 4-week forced-dose titration study 4. This trial evidence can support step therapy exception requests when a prescriber documents that the pharmacokinetic profile of lisdexamfetamine (a prodrug converted to d-amphetamine in the GI tract) provides therapeutic advantages over generic alternatives for a specific patient.

If your Cigna plan imposes step therapy, your prescriber can request a step therapy exception by submitting clinical documentation showing one of these scenarios: (1) the patient already tried and failed the required step medications, (2) the required step medication is medically contraindicated, or (3) the patient is currently stable on Vyvanse and switching would cause clinical harm.

How to Get Your Cigna PA Approved on the First Attempt

A clean, complete PA submission dramatically increases approval rates. Here is what the submission should include for the best chance of first-pass approval.

Start with the correct form. Cigna publishes drug-specific PA request forms on its provider portal. The Vyvanse form asks for the diagnosis, the requested dose (available in 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg capsules), the duration requested, and the clinical rationale. Generic prescriptions may use a different form or a simplified pathway.

According to the American Professional Society of ADHD and Related Disorders (APSARD), "prior authorization denials for ADHD stimulants are most commonly caused by incomplete documentation rather than lack of medical necessity" 5. Your prescriber should attach chart notes documenting the ADHD evaluation, prior medication trials with specific dates, doses, and reasons for discontinuation, and a statement of medical necessity explaining why lisdexamfetamine is the appropriate choice.

For BED indications, attach documentation of the DSM-5 diagnostic evaluation, any prior behavioral or pharmacological treatment, and a reference to the McElroy et al. key trial data. That trial (N=773) showed lisdexamfetamine 50 mg and 70 mg reduced binge eating days per week from a baseline of 4.70 to 1.35 and 1.02, respectively, compared to 2.51 for placebo (P<0.001 for both doses) 6.

Common reasons for Cigna PA denials include: missing diagnosis code, no documentation of prior stimulant trial (for plans with step therapy), dose exceeding the FDA-approved maximum (70 mg/day), or prescriber specialty not matching the plan's requirements (some plans require the prescriber to be a psychiatrist or neurologist for adult ADHD).

Appealing a Cigna Denial for Vyvanse

If Cigna denies your Vyvanse PA, you have the right to appeal. The process is structured and time-bound.

Cigna offers a two-level internal appeal process followed by an external independent review organization (IRO) evaluation. The first-level appeal must be filed within 180 days of the denial letter. You or your prescriber submit a written appeal with additional clinical documentation addressing the specific reason for the denial. Cigna must respond within 30 days for standard appeals or 72 hours for expedited (urgent) appeals.

If the first-level internal appeal is denied, you can file a second-level internal appeal. This review is conducted by a different clinical reviewer who was not involved in the original denial or first appeal. The timeline mirrors the first level: 30 days standard, 72 hours expedited.

After exhausting both internal levels, you can request an external review through an IRO. The IRO is an independent organization certified by your state's insurance department. The external reviewer examines the clinical evidence and makes a binding decision. According to data published by the National Association of Insurance Commissioners, external reviews overturn approximately 40% to 60% of prescription drug denials when the appeal includes strong clinical documentation [7].

Dr. Timothy Wilens, Chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital, has stated: "When appealing stimulant denials, the most effective strategy is to frame the appeal around the specific pharmacological properties that make the denied medication clinically distinct from the step-therapy alternatives" 8.

For Vyvanse specifically, the appeal should emphasize: (1) lisdexamfetamine's prodrug mechanism reduces abuse potential compared to immediate-release amphetamine formulations, (2) the smoother pharmacokinetic curve produces fewer peak-and-trough symptom fluctuations, and (3) for BED, no other FDA-approved pharmacological option exists.

Using the Takeda Savings Card With Cigna

Takeda, the manufacturer of brand-name Vyvanse, offers a copay savings card that can reduce out-of-pocket costs on commercially insured prescriptions. The card is not valid for patients enrolled in Medicare Part D, Medicaid, TRICARE, or other government-funded programs.

With the Takeda savings card, eligible commercially insured patients may pay as little as $30 per 30-day supply of brand Vyvanse. The card covers the difference between your plan copay and the $30 target, up to a maximum annual benefit (typically $60 per fill or a $3,600 annual cap, though terms change periodically).

To use the card with Cigna, present it at the pharmacy as a secondary payer. The pharmacy processes Cigna as the primary insurance and applies the savings card to the remaining copay. If Cigna's formulary routes you to the generic and your prescriber has not written "Dispense as Written" (DAW), the brand savings card will not apply because the pharmacy fills the generic.

One caution: savings card payments do not count toward your Cigna deductible or out-of-pocket maximum. This means you could reach the end of the plan year having paid substantial copays via the savings card without progressing toward your catastrophic coverage threshold.

With generic lisdexamfetamine now widely available at $30 to $50 per month cash price, the savings card's value proposition has narrowed. For many patients, the generic provides identical clinical efficacy at a lower net cost without the administrative complexity of managing a copay card.

Cigna Coverage for Vyvanse in Specific Clinical Scenarios

Cigna's coverage criteria vary depending on the indication and the patient population. Here is how the PA criteria apply to the most common scenarios.

ADHD in children ages 6 to 17: Cigna covers Vyvanse for pediatric ADHD when the prescriber documents a DSM-5 diagnosis and, on plans with step therapy, a prior trial of a generic stimulant. The AAP guideline recommends stimulant medication as first-line pharmacotherapy for ADHD in children ages 6 and older, with behavioral therapy as a co-intervention 2. Vyvanse's 10 mg starting dose and once-daily administration make it a common choice for this age group.

ADHD in adults: Adult ADHD coverage through Cigna follows similar PA criteria, though some plans add a requirement that the prescriber be a psychiatrist, neurologist, or have documented training in ADHD management. A 2021 meta-analysis in The Lancet Psychiatry (N=10,068 across 40 trials) found that lisdexamfetamine had the largest effect size among all ADHD medications for symptom reduction in adults (standardized mean difference: -0.93, 95% CI: -1.11 to -0.76) 9.

Binge eating disorder in adults: Cigna covers Vyvanse for BED at doses of 50 mg or 70 mg daily. Because Vyvanse is the only FDA-approved medication for BED, step therapy exceptions are typically granted with proper documentation. The approval is usually for 12 months with annual reauthorization.

Off-label uses: Cigna does not cover Vyvanse for weight loss as a standalone indication. The FDA label explicitly states that Vyvanse is not indicated for obesity, and Cigna's coverage criteria reflect this restriction 1. Prescriptions submitted with an obesity or overweight diagnosis code (E66.x) without an accompanying BED or ADHD diagnosis will be denied.

Generic Lisdexamfetamine vs. Brand Vyvanse on Cigna

The availability of generic lisdexamfetamine has shifted Cigna's formulary strategy for this medication.

Most Cigna commercial plans now list generic lisdexamfetamine at Tier 1 or Tier 2, with lower or no PA requirements. Brand Vyvanse remains at Tier 3 or Tier 4, and Cigna may apply mandatory generic substitution unless the prescriber writes "Dispense as Written" with a documented clinical reason. The cost difference is substantial: $35 average cash price for the generic versus $390 list price for the brand 10.

From a clinical standpoint, the FDA's bioequivalence requirements mean the generic must deliver lisdexamfetamine within 80% to 125% of the brand's pharmacokinetic parameters (AUC and Cmax) in a 90% confidence interval. For most patients, the switch produces no clinically meaningful difference in symptom control.

However, some patients report subjective differences after switching from brand to generic. If a patient experiences a documented change in clinical response after generic substitution, the prescriber can request a brand-medically-necessary exception through Cigna's PA process. This requires chart notes documenting the timeline of the switch, the clinical change observed, and the rationale for returning to brand.

The practical recommendation: start with generic lisdexamfetamine on Cigna. It occupies a better formulary position, costs less, and often requires less administrative burden. Reserve the brand PA process for the minority of patients who demonstrate a clinical need for it.